Developer docs
API playgroundTry for free, no card

Search company profiles

Marinus Pharmaceuticals

Full company profile

uuid0004fzv

Namestring
Marinus Pharmaceuticals
Legal namestring
Marinus Pharmaceuticals, Inc.
Company typeenum
Public
Founded yearint
2012
Descriptiontext

Marinus Pharmaceuticals, Inc. was a Delaware-incorporated, publicly traded biopharmaceutical company (NASDAQ: MRNS) headquartered in Branford, Connecticut, with 51-100 employees. The company reformulated, developed, and commercialized therapeutics for neurological, psychiatric, and pain disorders, with its entire commercial focus centered on ZTALMY (ganaxolone oral suspension) — the first and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD), a rare developmental epileptic encephalopathy. Ganaxolone is a proprietary neuroactive steroid that acts as a positive allosteric modulator of GABA-A receptors, and ZTALMY was approved for patients aged two years and older.

The company's business model centered on direct commercialization of ZTALMY through US specialty pharmacy channels following March 2022 FDA approval, supplemented by international distribution via regional partners — including Immedica Pharma in Europe/UK and Tenacia Biopharmaceuticals/Golden Age Health in Mainland China following the 2024 NMPA approval. Capital was raised through a mix of debt financing (notably $30 million from Oaktree Capital Management and $32.5 million in revenue interest financing from Sagard Healthcare Partners), a $60 million post-IPO equity offering in November 2022, and earlier venture rounds. In January 2025, Marinus was acquired by Swedish rare disease company Immedica Pharma AB for approximately $151 million in a cash tender offer at $0.55 per share, representing a 48% premium over the prior closing price.

Short descriptiontext

Marinus Pharmaceuticals was a publicly traded biopharmaceutical company that developed and commercialized ZTALMY (ganaxolone), the first FDA-approved treatment for seizures associated with CDKL5 deficiency disorder, serving pediatric patients with this rare genetic neurological condition before being acquired by Immedica Pharma in 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBranford, United States
HQ citystring
Branford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
rare disease therapeutics, neurological disorder treatments, epilepsy seizure therapy, specialty pharmaceutical products, CDKL5 deficiency disorder drug
Industry2 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKAIAB
Epilepsy & Seizure Disorders
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Rare Neurological Disease Pharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue generated from sales of ZTALMY (ganaxolone) in the US market following FDA approval. The product is comercializado through specialty pharmacy channels.

thepharmaletter.com
2Revenue Interest Financing
TypeTransaction Fee
Description

Non-dilutive capital arrangement with Sagard Healthcare Partners involving tiered payments based on U.S. net sales of ganaxolone, providing upfront capital while maintaining product revenue potential.

biospace.com
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1ZTALMY (ganaxolone)
Description

FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD). The first and only approved treatment for CDKL5 deficiency disorder in the United States.

thepharmaletter.com
Core offering1 text field

Marinus Pharmaceuticals reformulated, developed, and commercialized ZTALMY (ganaxolone) oral suspension, the first and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients aged two years and older. The company focused on rare neurological and epileptic encephalopathy indications, holding regulatory approvals in the United States, European Union, United Kingdom, and China. Following FDA approval in 2022, the product was commercialized through US specialty pharmacy channels and through regional partners internationally.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • First FDA-approved treatment for CDKL5 deficiency disorder seizures
Product overview1 text field

Marinus Pharmaceuticals was a pharmaceutical company focused on rare neurological diseases. The company's primary product was ZTALMY (ganaxolone), an FDA-approved oral suspension medication for treating seizures associated with CDKL5 deficiency disorder. Following acquisition by Immedica Pharma in 2025, ZTALMY became part of Immedica's rare disease portfolio within the RARE Neurology therapeutic area.

Product and service1 record
1ZTALMY (ganaxolone) oral suspension
CategoryRare neurological disease prescription drug
Description

ZTALMY (ganaxolone) is an FDA-approved oral suspension medication for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), a rare developmental and epileptic encephalopathy. It is the first and only FDA-approved therapy for CDD seizures, indicated for patients aged two years and older, and is distributed through US specialty pharmacy channels. The active pharmaceutical ingredient, ganaxolone, is a neuroactive steroid that acts as a positive allosteric modulator of GABA-A receptors.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Tenacia Biopharmaceuticals
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-02-01
Description

Commercialization agreement granting exclusive rights to Golden Age Health for ZTALMY (ganaxolone oral suspension) in Mainland China, marking the first and only approved treatment for CDKL5 deficiency disorder in China.

businesswire.com
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-01
Description

Exclusive commercialization rights for ZTALMY in Mainland China, leveraging GAH's patient-focused platform to accelerate access for families affected by CDKL5 deficiency disorder, listed in China's National Rare Disease Catalog.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Specialty biopharma with leading rare epilepsy franchise (Epidiolex/Xywav) following the GW Pharmaceuticals acquisition. Comparable as a competitor in the same rare pediatric epilepsy commercial landscape.

TypeEmerging player
Description

Neurology-focused biopharma developing therapies for rare developmental and epileptic encephalopathies, directly overlapping Marinus' therapeutic area and target indications.

TypeBroad incumbent
Description

Global neurology-focused biopharma with established rare epilepsy franchise (post-Zogenix acquisition). Comparable in CNS specialty commercial scale, regulatory strategy, and rare pediatric epilepsy focus.

TypeBroad incumbent
Description

Specialty neurology biopharma with a portfolio across epilepsy, migraine, and rare neurological disorders. Comparable as a CNS-focused commercial partner with established rare neurology distribution capabilities.

5Zogenix (UCB)
TypeDirect peer
Description

Developed FINTEPLA (fenfluramine) for Dravet syndrome and Lennox-Gastaut syndrome, two rare developmental and epileptic encephalopathies that overlap mechanistically and clinically with CDD. Acquired by UCB in 2022 for ~$1.9B.

TypeOthers
Description

Swedish rare disease specialty pharma and parent company of Marinus following the 2025 acquisition. Comparable as the commercial platform now responsible for ZTALMY's continued global commercialization in rare neurology.

TypeDirect peer
Description

CNS-focused biopharma developing neuroactive steroid GABA-A modulators (e.g., ZULRESSO, ZURZUVAE). Closest mechanistic peer to ganaxolone given shared GABA-A PAM pharmacology and neurology/CNS positioning.

TypeBroad incumbent
Description

Established rare disease biopharma with a portfolio of orphan therapies across multiple therapeutic areas including neurology. Comparable as a commercial-stage rare disease specialist with similar regulatory and pricing dynamics.

TypeDirect peer
Description

Developed Epidiolex (cannabidiol) for rare pediatric epilepsies, the closest precedent for a CNS-focused rare-epilepsy franchise. Jazz acquired GW in 2021 and now competes commercially with Marinus/ZTALMY in adjacent orphan seizure indications.

TypeEmerging player
Description

Clinical and commercial-stage rare disease biopharma developing therapies for rare genetic and neurological disorders. Comparable as a rare-disease focused commercial-stage peer with similar regulatory and reimbursement dynamics.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Marinus Pharmaceuticals

Rare Neurological Disease Pharmaceuticalsmarinuspharma.com

Marinus Pharmaceuticals was a publicly traded biopharmaceutical company that developed and commercialized ZTALMY (ganaxolone), the first FDA-approved treatment for seizures associated with CDKL5 deficiency disorder, serving pediatric patients with this rare genetic neurological condition before being acquired by Immedica Pharma in 2025.

What Marinus Pharmaceuticals does

Marinus Pharmaceuticals, Inc. was a Delaware-incorporated, publicly traded biopharmaceutical company (NASDAQ: MRNS) headquartered in Branford, Connecticut, with 51-100 employees. The company reformulated, developed, and commercialized therapeutics for neurological, psychiatric, and pain disorders, with its entire commercial focus centered on ZTALMY (ganaxolone oral suspension) — the first and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD), a rare developmental epileptic encephalopathy. Ganaxolone is a proprietary neuroactive steroid that acts as a positive allosteric modulator of GABA-A receptors, and ZTALMY was approved for patients aged two years and older.

The company's business model centered on direct commercialization of ZTALMY through US specialty pharmacy channels following March 2022 FDA approval, supplemented by international distribution via regional partners — including Immedica Pharma in Europe/UK and Tenacia Biopharmaceuticals/Golden Age Health in Mainland China following the 2024 NMPA approval. Capital was raised through a mix of debt financing (notably $30 million from Oaktree Capital Management and $32.5 million in revenue interest financing from Sagard Healthcare Partners), a $60 million post-IPO equity offering in November 2022, and earlier venture rounds. In January 2025, Marinus was acquired by Swedish rare disease company Immedica Pharma AB for approximately $151 million in a cash tender offer at $0.55 per share, representing a 48% premium over the prior closing price.

Marinus Pharmaceuticals firmographics

Firmographics
Name
Marinus Pharmaceuticals
Legal name
Marinus Pharmaceuticals, Inc.
Website
https://marinuspharma.com
Company type
Public
Founded year
2012
Operating status
Acquired
Headcount range
51–100 employees
Short description
Marinus Pharmaceuticals was a publicly traded biopharmaceutical company that developed and commercialized ZTALMY (ganaxolone), the first FDA-approved treatment for seizures associated with CDKL5 deficiency disorder, serving pediatric patients with this rare genetic neurological condition before being acquired by Immedica Pharma in 2025.
Ownership category
akta.pro rank

Marinus Pharmaceuticals industry classification

Industry
Product category
Rare Neurological Disease Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKAIAB
Epilepsy & Seizure Disorders

Keywords

  • Rare disease therapeutics
  • Neurological disorder treatments
  • Epilepsy seizure therapy
  • Specialty pharmaceutical products
  • CDKL5 deficiency disorder drug

Where Marinus Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Branford
HQ country
United States
HQ region
North America

Markets served

Marinus Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Revenue generated from sales of ZTALMY (ganaxolone) in the US market following FDA approval. The product is comercializado through specialty pharmacy channels.
  2. Revenue Interest Financing: Non-dilutive capital arrangement with Sagard Healthcare Partners involving tiered payments based on U.S. net sales of ganaxolone, providing upfront capital while maintaining product revenue potential.

Go-to-market motion2 records

Distribution channels1 record

Marinus Pharmaceuticals product offering

Product offering

Core offering

Marinus Pharmaceuticals reformulated, developed, and commercialized ZTALMY (ganaxolone) oral suspension, the first and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients aged two years and older. The company focused on rare neurological and epileptic encephalopathy indications, holding regulatory approvals in the United States, European Union, United Kingdom, and China. Following FDA approval in 2022, the product was commercialized through US specialty pharmacy channels and through regional partners internationally.

Product overview

Marinus Pharmaceuticals was a pharmaceutical company focused on rare neurological diseases. The company's primary product was ZTALMY (ganaxolone), an FDA-approved oral suspension medication for treating seizures associated with CDKL5 deficiency disorder. Following acquisition by Immedica Pharma in 2025, ZTALMY became part of Immedica's rare disease portfolio within the RARE Neurology therapeutic area.

Differentiator

Problem solved

Functional benefit

Brands

  • ZTALMY (ganaxolone): FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD). The first and only approved treatment for CDKL5 deficiency disorder in the United States.

Products and services

  • ZTALMY (ganaxolone) oral suspension ZTALMY (ganaxolone) is an FDA-approved oral suspension medication for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), a rare developmental and epileptic encephalopathy. It is the first and only FDA-approved therapy for CDD seizures, indicated for patients aged two years and older, and is distributed through US specialty pharmacy channels. The active pharmaceutical ingredient, ganaxolone, is a neuroactive steroid that acts as a positive allosteric modulator of GABA-A receptors.

Quantifiable outcome

  • First FDA-approved treatment for CDKL5 deficiency disorder seizures

Companies that use Marinus Pharmaceuticals

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Marinus Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Marinus Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered major.

  • Tenacia BiopharmaceuticalsmajorStrategic or Co-development Partner · 1 February 2026Commercialization agreement granting exclusive rights to Golden Age Health for ZTALMY (ganaxolone oral suspension) in Mainland China, marking the first and only approved treatment for CDKL5 deficiency disorder in China.
  • Golden Age HealthmajorChannel Partner/ Reseller/ Distributor · 1 February 2026Exclusive commercialization rights for ZTALMY in Mainland China, leveraging GAH's patient-focused platform to accelerate access for families affected by CDKL5 deficiency disorder, listed in China's National Rare Disease Catalog.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Marinus Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Jazz Pharmaceuticals: Specialty biopharma with leading rare epilepsy franchise (Epidiolex/Xywav) following the GW Pharmaceuticals acquisition. Comparable as a competitor in the same rare pediatric epilepsy commercial landscape.
  • UCB: Global neurology-focused biopharma with established rare epilepsy franchise (post-Zogenix acquisition). Comparable in CNS specialty commercial scale, regulatory strategy, and rare pediatric epilepsy focus.
  • Lundbeck: Specialty neurology biopharma with a portfolio across epilepsy, migraine, and rare neurological disorders. Comparable as a CNS-focused commercial partner with established rare neurology distribution capabilities.
  • BioMarin Pharmaceutical: Established rare disease biopharma with a portfolio of orphan therapies across multiple therapeutic areas including neurology. Comparable as a commercial-stage rare disease specialist with similar regulatory and pricing dynamics.

Emerging players

  • Ovid Therapeutics: Neurology-focused biopharma developing therapies for rare developmental and epileptic encephalopathies, directly overlapping Marinus' therapeutic area and target indications.
  • Ultragenyx Pharmaceutical: Clinical and commercial-stage rare disease biopharma developing therapies for rare genetic and neurological disorders. Comparable as a rare-disease focused commercial-stage peer with similar regulatory and reimbursement dynamics.

Direct peers

  • Zogenix (UCB): Developed FINTEPLA (fenfluramine) for Dravet syndrome and Lennox-Gastaut syndrome, two rare developmental and epileptic encephalopathies that overlap mechanistically and clinically with CDD. Acquired by UCB in 2022 for ~$1.9B.
  • Sage Therapeutics: CNS-focused biopharma developing neuroactive steroid GABA-A modulators (e.g., ZULRESSO, ZURZUVAE). Closest mechanistic peer to ganaxolone given shared GABA-A PAM pharmacology and neurology/CNS positioning.
  • GW Pharmaceuticals (Jazz Pharmaceuticals): Developed Epidiolex (cannabidiol) for rare pediatric epilepsies, the closest precedent for a CNS-focused rare-epilepsy franchise. Jazz acquired GW in 2021 and now competes commercially with Marinus/ZTALMY in adjacent orphan seizure indications.

Others

  • Immedica Pharma AB: Swedish rare disease specialty pharma and parent company of Marinus following the 2025 acquisition. Comparable as the commercial platform now responsible for ZTALMY's continued global commercialization in rare neurology.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Marinus Pharmaceuticals social profiles

Digital presence

Marinus Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Marinus Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles7 records

Marinus Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Marinus Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Marinus Pharmaceuticals

What does Marinus Pharmaceuticals do?

Marinus Pharmaceuticals reformulated, developed, and commercialized ZTALMY (ganaxolone) oral suspension, the first and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients aged two years and older. The company focused on rare neurological and epileptic encephalopathy indications, holding regulatory approvals in the United States, European Union, United Kingdom, and China. Following FDA approval in 2022, the product was commercialized through US specialty pharmacy channels and through regional partners internationally.

Is Marinus Pharmaceuticals a public or private company?

Marinus Pharmaceuticals is a public company. It is classified as corporate owned and is currently acquired.

When was Marinus Pharmaceuticals founded?

Marinus Pharmaceuticals was founded in 2012. It employs 51 to 100 people.

Where is Marinus Pharmaceuticals based?

Marinus Pharmaceuticals is headquartered in Branford, United States, in the North America region.

How does Marinus Pharmaceuticals make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are revenue Interest Financing.

Who are Marinus Pharmaceuticals's main competitors?

Broad incumbents on record are Jazz Pharmaceuticals, UCB, Lundbeck and BioMarin Pharmaceutical. Emerging players are Ovid Therapeutics and Ultragenyx Pharmaceutical. Direct peers are Zogenix (UCB), Sage Therapeutics and GW Pharmaceuticals (Jazz Pharmaceuticals). Immedica Pharma AB is listed as an others.

Does Marinus Pharmaceuticals have an API?

No public API is recorded for Marinus Pharmaceuticals.

What industry is Marinus Pharmaceuticals in?

Marinus Pharmaceuticals's product category is Rare Neurological Disease Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAKAIAB, Epilepsy & Seizure Disorders. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comImmedica publishes Business Review and Annual & Sustainability Report 2025Immedica published its 2025 Business Review and Annual & Sustainability Report, citing pro forma net sales of EUR 134.5 million. The company expanded its portfolio through acquisitions of Marinus Pharmaceuticals and a definitive agreement to acquire Neurocrine Group, and was certified as a Great Place To Work for the third consecutive year.TfscroTop 10 Emerging East Coast Biotech Companies to Watch in 2025TFS HealthScience highlights ten emerging biotech companies on the U.S. East Coast ahead of the 2025 OCT conference, noting strategic developments such as Marinus Pharmaceuticals' acquisition by Immedica Pharma AB and Castle Creek Biosciences securing $75 million in financing. The article emphasizes the region's role as a global life sciences hub, detailing pipeline advancements and regulatory milestones for firms including EvolveImmune Therapeutics, OnCusp Therapeutics, and Cognition Therapeutics. These entities are recognized for their innovative approaches to rare diseases, oncology, and neurodegenerative disorders.news.cision.comImmedica completes acquisition of Marinus Pharmaceuticals, Inc.Immedica completed its acquisition of Marinus Pharmaceuticals, paying $0.55 per share in cash for all outstanding shares. Marinus, a seizure-disorder drug developer, will cease trading on Nasdaq and become an indirect wholly owned subsidiary. The deal is subject to appraisal rights.Investing.comMarinus Pharmaceuticals director sells shares worth $869 By Investing.comMarinus Pharmaceuticals director Marvin Johnson sold 1,610 shares at $0.54 each, totaling $869, under a pre-arranged plan. The stock has fallen 94.5% over the past year, with market cap near $30 million. The company is nearing a $151 million acquisition of Immedica Pharma.citybizImmedica to Acquire Marinus PharmaceuticalsImmedica Pharma AB has agreed to acquire Marinus Pharmaceuticals, Inc. through a tender offer for USD 0.55 per share, representing an implied enterprise value of approximately USD 151 million. The acquisition adds ZTALMY (ganaxolone), an FDA-approved treatment for seizures associated with CDKL5 deficiency disorder, to Immedica's rare disease portfolio and provides immediate entry into the North American market with a revenue-generating commercial product. The transaction, expected to close in Q1 2025, represents a 48% premium over Marinus' closing share price and culminates the strategic alternatives review Marinus announced in October 2024.YahooMarinus Pharmaceuticals to be acquired by Immedica for 55c per shareImmedica agreed to acquire Marinus Pharmaceuticals via a cash tender offer at 55c per share, a 48% premium over the last trading price. The deal, valued at approximately $151M, is expected to close in Q1 2025 and adds global rights to Zealmy, a rare neurology medicine.ImmedicaImmedica to acquire biopharmaceutical company Marinus Pharmaceuticals, Inc.Immedica agreed to acquire Marinus Pharmaceuticals via a tender offer at $0.55 per share, adding ZTALMY (ganaxalone) to its portfolio. The deal, expected to close in Q1 2025, adds a commercial-stage rare disease product in the U.S. and expands Immedica's North American presence.YahooImmedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.Immedica agreed to acquire Marinus Pharmaceuticals via a tender offer at $0.55 per share, adding ZTALMY, an FDA-approved treatment for CDKL5 deficiency disorder seizures. The deal, expected to close in Q1 2025, adds a commercial-stage asset in the U.S. and expands Immedica's rare disease portfolio.YahooImmedica to Acquire Marinus Pharmaceuticals in $151 Million Deal; Shares Surge 43%Immedica agreed to acquire Marinus Pharmaceuticals for over $151 million, offering $0.55 per share, a 48% premium over the closing price. Marinus shares rose 43% to $0.53, and the deal is expected to close in Q1 2025.AInvestImmedica's $151M Acquisition of Marinus Pharmaceuticals Boosts Rare Disease Portfolio and Revenue GrowthImmedica Pharma AB announced a $151 million acquisition of Marinus Pharmaceuticals, expected to close in Q1 2025. The deal adds ZTALMY, a FDA-approved treatment for CDKL5 deficiency disorder seizures, to Immedica's portfolio. The acquisition is expected to drive revenue growth and expand Immedica's North American presence.